Reply
Annabel Blasi, Virginia Hernandez‐Gea, Juan Carlos Reverter, Juan Carlos Garcia‐Pagán – 25 November 2015
Down‐regulation of the cyclin‐dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis
Hui Guo, Li Jing, Yangzi Cheng, Vassilis Atsaves, Yi Lv, Tao Wu, Rujuan Su, Yamin Zhang, Ronghua Zhang, Wenbin Liu, George Z. Rassidakis, Yongchang Wei, Kejun Nan, Francois X. Claret – 25 November 2015 – Down‐regulation of p57 (KIP2) cyclin‐dependent kinase inhibitors accelerates the growth and invasion of hepatocellular carcinoma (HCC), suggesting that p57 may play an important role in liver carcinogenesis. However, the mechanism or oncogenic signal leading to p57 down‐regulation in HCC remains to be determined.
Quality of anticoagulation and outcome of bleeding in cirrhosis
Xingshun Qi, Valerio De Stefano, Xiaozhong Guo – 25 November 2015
Hepatology highlights
Jean‐François Dufour – 25 November 2015
Stemness and reprogramming in liver cancer
Snorri S. Thorgeirsson – 24 November 2015
Reply
Chong‐Gee Teo, Ajay Yesupriya, Man‐Huei Chang, Lyna Zhang – 24 November 2015
PI3K/AKT/mTOR‐dependent stabilization of oncogenic far‐upstream element binding proteins in hepatocellular carcinoma cells
Jana Samarin, Vibor Laketa, Mona Malz, Stephanie Roessler, Ilan Stein, Elad Horwitz, Stephan Singer, Eleni Dimou, Antonio Cigliano, Michaela Bissinger, Christine Susanne Falk, Xin Chen, Steven Dooley, Eli Pikarsky, Diego Francesco Calvisi, Carsten Schultz, Peter Schirmacher, Kai Breuhahn – 24 November 2015 – Transcription factors of the far‐upstream element‐binding protein (FBP) family represent cellular pathway hubs, and their overexpression in liver cancer (hepatocellular carcinoma [HCC]) stimulates tumor cell proliferation and correlates with poor prognosis.
Serial changes of cytokines and growth factors in peripheral circulation after right lobe donor hepatectomy
Shridhar Vasantrao Sasturkar, Paul David, Shreya Sharma, Shiv Kumar Sarin, Nirupama Trehanpati, Viniyendra Pamecha – 24 November 2015 – Cytokines and growth factors have prominent roles in liver regeneration. The aim of this study was to evaluate the biological markers of liver regeneration in healthy donors undergoing right lobe donor hepatectomy for living donor liver transplantation. Twenty‐five voluntary liver donors were enrolled. Peripheral blood samples were taken a day before the operation and on postoperative days (PODs) 1, 3, 7, 14, and 42.
Can rechallenge be done safely after mild or moderate drug‐induced liver injury?
John R. Senior – 24 November 2015
Nonselective β‐blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients
Lars Bossen, Aleksander Krag, Hendrik Vilstrup, Hugh Watson, Peter Jepsen – 24 November 2015 – The safety of nonselective β‐blockers (NSBBs) in advanced cirrhosis has been questioned. We used data from three satavaptan trials to examine whether NSBBs increase mortality in cirrhosis patients with ascites. The trials were conducted in 2006‐2008 and included 1198 cirrhosis patients with ascites followed for 1 year.